IP Library › Granted Patent US 10,851,380
Granted Patent B2
US 10,851,380 · App. 14/685,568 · Granted Dec 1, 2020

Methods for cleaving a target DNA using a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein

Inventors: Jin-Soo Kim (Seoul, KR); Seung Woo Cho (Seoul, KR); Sojung Kim (Seoul, KR)
Assignee: TOOLGEN INCORPORATED
C12N15/52C12N9/16C12N9/22C12N15/102C12N15/111C12N15/63C12N15/8216C12N15/85C12N15/907C12Y301/21C12N2310/10C12N2310/20C12N2310/531
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,851,380
App. No.
14/685,568
Granted
Dec 1, 2020
Kind
B2
Abstract

The present invention relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present invention relates to a composition for cleaving a target DNA in eukaryotic cells or organisms comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof.

Claims (13)

1. A method of introducing a site-specific, double-stranded break at a target nucleic acid sequence in a eukaryotic cell, the method comprising introducing into the eukaryotic cell a Type II Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas system, wherein the CRISPR/Cas system comprises:

a) a nucleic acid encoding a Cas9 polypeptide comprising a nuclear localization signal, wherein the nucleic acid is codon-optimized for expression in eukaryotic cells, and

b) a guide RNA that hybridizes to the target nucleic acid, wherein the guide RNA is a chimeric guide RNA comprising a CRISPR RNA (crRNA) portion fused to a trans activating crRNA (tracrRNA) portion, wherein the guide RNA comprises two guanines at its 5′ end, and there are no additional nucleic acid residues between the two guanines at the 5′ end and the crRNA portion of the guide RNA;

whereby a site-specific, double stranded break at the target nucleic acid sequence is introduced.

2. The method of claim 1 , wherein the nuclear localization signal is located at the C terminus of the Cas9 polypeptide.

3. The method of claim 1 , wherein the eukaryotic cell is a mammalian cell.

4. The method of claim 3 , wherein the mammalian cell is a human cell.

5. The method of claim 1 , wherein the nucleic acid encoding the Cas 9 polypeptide is codon-optimized for expression in mammalian cells.

6. The method of claim 1 , wherein the target nucleic acid sequence is a genomic sequence located at its endogenous site in the genome of the eukaryotic cell.

7. The method of claim 1 , wherein the nucleic acid encoding the Cas9 polypeptide is a vector.

8. The method of claim 1 , wherein the Cas9 polypeptide is a Streptococcus pyogenes Cas9 polypeptide.

9. The method of claim 1 , wherein the nucleic acid encoding the Cas9 polypeptide is introduced into the eukaryotic cell before introducing the guide RNA into the eukaryotic cell.

10. The method of claim 1 , wherein the Cas9 polypeptide is a Streptococcus Cas9 polypeptide.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2015
From: KIM, JIN-SOO; CHO, SEUNG WOO; KIM, SOJUNG; KIM, JONG MIN; KIM, SEOKJOONG
To: TOOLGEN INCORPORATED
Reel/Frame 035886/0509 →
Continuity (5)
Continuation PCTKR2013009488 · Oct 23, 2013
Provisional Application 61837481 · Jun 20, 2013
Provisional Application 61803599 · Mar 20, 2013
Provisional Application 61717324 · Oct 23, 2012
Related Publication 20150322457A1 · Nov 12, 2015
Cited By (11)
US 12,201,699 US 12,215,343 US 12,338,436 US 12,473,559 US 12,606,832 US 12,612,633 US 12,612,634 US 12,612,643 US 12,630,838 US 12,637,690 US 12,649,928